|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 The Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania; and the Eagleville Sanatorium, Eagleville, Pennsylvania.
Potassium para-aminosalicylate (KPAS) was administered to 120 patients with tuberculosis.
One hundred fifteen (96 per cent) tolerated 12 gm. daily doses of KPAS without difficulty. There were no evidences of potassium toxicity.
Plasma PAS concentration studies revealed that KPAS is more rapidly absorbed and yields significantly higher values than either PAS or NaPAS.
KPAS is ideally suited for use in patients with congestive heart failure, pregnancy, or other situations in which use of the sodium salt is precluded.
The 10 per cent solution of KPAS was used for "desensitizations" of those who had acquired sensitivity reactions to PAS compounds.
It is concluded that KPAS is superior to other forms of PAS.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |